TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04564768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Cancer Recovery (MBCR)
Description: Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
Study: NCT02282345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study: NCT03597646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold Inspiratory Muscle Trainer
Study: NCT03303027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6-0 fast absorbing gut suture
Description: Fast absorbing surgical gut suture is a strand of collagenous material, size 6-0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-0 fast absorbing gut suture
Description: Fast absorbing surgical gut suture is a strand of collagenous material, size 5-0
Study: NCT03876301

Intervention type: DRUG
Intervention: Standard of Care FVIII Replacement therapy
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
Study: NCT03023670

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiopulmonary bypass
Description: Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiopulmonary bypass
Description: Low rate (4\\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
Study: NCT02983097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatinum 100 mg / m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatinum AUC5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2000 mg/m², administered twice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5-20 mg administered either d1-d7, or d-6-d7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegFilgrastim
Description: PegFilgrastim 6 mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral stem cell collection
Description: collection of peripheral stem cells for autologous stem cell transplantation
Study: NCT00924781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline
Description: MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline
Description: MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline
Description: MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline
Description: MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
Description: MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
Description: MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
Study: NCT00499057

Intervention type: RADIATION
Group type: OTHER
Intervention: interstitial high dose-rate brachytherapy, PBI
Description: Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
Study: NCT03779243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 5mg and Sleep Education
Description: Melatonin 5mg daily and sleep education for 6 weeks following injury or surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo pills for 6 weeks following injury or surgery.
Study: NCT01155882

Intervention type: PROCEDURE
Intervention: Whipple at the Splenic Artery (WATSA)
Study: NCT02802670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GDC-0810
Description: Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of \[14C\]-labeled GDC-0810 on Day 1.
Study: NCT00742781

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral supplementation daily with up to 5000 IU over 6 months.
Study: NCT03660878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.5%)
Description: Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.
Study: NCT01813175

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk II
Description: Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
Study: NCT03312218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spaced educational intervention
Description: A spaced educational intervention will be provided to participants
Study: NCT00991965

Intervention type: DEVICE
Intervention: INFUSE® Bone Graft
Description: Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
Study: NCT01332864

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: O OMT applied to areas of somatic dysfunction other than the head region.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: O OMT applied to areas of somatic dysfunction other than the head region.
Study: NCT01813175

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk - control
Description: Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
Study: NCT01913353

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA BN®
Description: 0.5 ml MVA BN® with a nominal titer of 1x10E8 TCID50, administered as a subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM2000®
Description: 0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACAM2000®
Description: 0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
Study: NCT02143648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER tablets 60 mg BID
Description: nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER tablets 120mg BID
Description: nalbuphine HCl ER tablets 120mg BID administered for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets BID
Description: Placebo tablets BID administered for 8 weeks
Study: NCT03954210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: CBT-I is an in-person, one-on-one program with a graduate psychology research assistant who is trained in providing a standardized CBT-I. Participants will maintain a sleep diary during the course of the program to aid in tailoring the program. Each session will begin with a summary and graphing of sleep diary data and will include an assessment of treatment gains and adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and Lifestyle Education
Description: Participants in the sleep and lifestyle education group will attend six weekly, in-person, one-on-one, stretching, and thinking activity sessions with a graduate research assistant to control for socialization and contact with research personnel.
Study: NCT04488952

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nerve block combined with general anesthesia
Description: Patients in this group receive nerve block combined with general anesthesia.
Study: NCT00267241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
Study: NCT02318004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
Study: NCT04710108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Communication
Description: Spoken word poem set to video images performed by author. Comic book was transformed from the video that was equivalent in content to the video.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Communication
Description: Spoken word poem set to video images performed by author. Comic book was transformed from the video that was equivalent in content to the video.
Study: NCT01836861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145
Study: NCT00566306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyhexamethyleneguanidine (PHMG)
Description: 6 months in 3 experimental wards
Study: NCT02562729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve-Sparing Radical Hysterectomy
Description: Type C1 NSRH Removal indwelling catheter on day 4 after surgery
Study: NCT01332864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: O OMT applied to areas of somatic dysfunction other than the head region.
Study: NCT04488952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nerve block combined with general anesthesia
Description: Patients in this group receive nerve block combined with general anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nerve block combined with general anesthesia
Description: Patients in this group receive nerve block combined with general anesthesia.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: spinal anesthesia
Description: Patients in this group receive spinal anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: Patients in this group receive spinal anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: Patients in this group receive spinal anesthesia.
Study: NCT01182363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Solve Education
Description: Problem solving education (PSE), a brief skills-building psychotherapeutic intervention that focuses on specific daily problems, and applies to these problems a structured approach to finding and evaluating solutions, is one such problem solving approach. Problem solving education differs from other problem solving interventions in that it can be conducted by a variety of health providers, who do not have specific training as mental health clinicians. Sessions are fairly brief (approximately 30 minutes in length) and positive, sustained effects have been achieved in 6-8 sessions. Problem solving education's success is based on premise that strong problem solving abilities promote a sense of control and self-efficacy and buffer the negative effects of life stressors.
Study: NCT03732547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 mAb
Description: Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyIC
Description: Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
Study: NCT01332864

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Light touch
Description: Light touch applied to head region for 10 minutes with patient supine at rest.
Study: NCT03430869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 AV-45
Description: In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18-THK-5351
Description: In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
Study: NCT01305018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA
Description: 7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
Study: NCT01977287

Intervention type: DEVICE
Intervention: Functional Electrical Stimulation

Intervention type: DEVICE
Intervention: Ankle Foot Orthosis
Study: NCT02705703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAPA-pulsed DC vaccine
Description: A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
Study: NCT03704740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Description: Purified inactivated influenza virus surface antigens of four strains (quadrivalent)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal
Description: Influenza virus surface antigens of three strains (trivalent)
Study: NCT02624596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
Study: NCT02226900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Revascularization
Description: Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Coronary Artery Bypass Surgery
Description: On pump coronary artery by-pass surgery
Study: NCT01936610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: role play
Description: In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
Study: NCT02697045

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole 400mg LAI
Description: Aripiprazole 400mg, IM, Once a month
Study: NCT01800370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Description: Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds.
Study: NCT01305018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 7 g of leucine + 7 g of alanine per day during 9 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 g of alanine per day during 9 days
Study: NCT04058080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bikram Yoga
Description: Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6C, 40% humidity). The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration. Participants were able to attend any of the offered classes each week. Participants had approximately 18-22 classes in total to choose from each week.
Study: NCT05729529

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipoid acid gel
Description: Topic lipoid acid gel used with topic oral gel used on tongue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral gel used on tongue
Study: NCT01135446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 1 mg, once on Day 1 only, 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days
Study: NCT01409278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration and saline infusion.
Description: 50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour